Trials / Conditions / Myelodysplastic Syndrome With Isolated Del(5q)

Myelodysplastic Syndrome With Isolated Del(5q)

11 registered clinical trials studyying Myelodysplastic Syndrome With Isolated Del(5q) — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Biocollection in MyeloDysplastic Syndrome (P-MDS) NCT04869683	University Hospital, Brest	N/A
Unknown	Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes NCT04701229	University Hospital, Brest	—
Completed	WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950	Mayo Clinic	Phase 2
Completed	Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukem NCT01869114	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Completed	Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS NCT01141725	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS NCT00839982	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744	Fred Hutchinson Cancer Center	N/A
Completed	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With NCT00322101	Fred Hutchinson Cancer Center	Phase 3